Pulmonary embolism

7 trials 2 recruiting MedDRA PT
7 Registered trials
2 Recruiting
6 Unique sponsors
3 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
B Haematology (ATC B) 2
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Factor Xa inhibitor (DOAC) 1 substance
Phase III: 2 Phase IV: 4 Other: 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

2 trials
  • Assistance Publique Hopitaux De Paris Academic
    ALTEPLASE
    2024-511321-54-00 8 countries 2021 n=760
    Ended
  • Centre Hospitalier Regional Et Universitaire De Brest Academic
    IMP not specified
    2023-504486-23-00 2 countries 2024 n=750
    Recruiting

Phase IV

4 trials
  • Hospital General Universitario Dr. Balmis Academic
    IOMEPROL
    2024-515246-17-00 1 country 2024 n=150
    Ended
  • Insel Gruppe AG Academic
    RIVAROXABAN
    2023-507801-32-00 3 countries 2026 n=76
    Recruiting
  • Rigshospitalet Academic
    IMP not specified
    2022-502402-32-00 1 country n=65,000
    Ended
  • Rigshospitalet Academic
    ALTEPLASE
    2024-515712-45-00 1 country n=210
    Pending

Other

1 trial
  • Celon Pharma S.A. Commercial
    IMP not specified
    2024-519660-40-00 1 country 2025 n=38
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Rigshospitalet Academic 2 Phase IV 0
Celon Pharma S.A. Commercial 1 Other 0
Assistance Publique Hopitaux De Paris Academic 1 Phase III 0
Centre Hospitalier Regional Et Universitaire De Brest Academic 1 Phase III 1
Hospital General Universitario Dr. Balmis Academic 1 Phase IV 0
Insel Gruppe AG Academic 1 Phase IV 1
New trials by year
2021
1
2024
2
2025
1
2026
1
← All indication landscapes